34
Adenosine & adenosine receptors : Newer therapeutic perspective Dr Suyash Bharat Sharma PG JR 3 rd Pharmacology

Adenosine and adenosine receptors

Embed Size (px)

Citation preview

Page 1: Adenosine and adenosine receptors

Adenosine & adenosine receptors : Newer therapeutic perspective

Dr Suyash Bharat SharmaPG JR 3rd Pharmacology

Page 2: Adenosine and adenosine receptors

Introduction

• Adenosine is a metabolite of adenosine triphosphate (ATP)

• It accumulates in the area where ATP is utilised but not reformed, eg- ischemia

• Exists free in cytosol• ‘Homeostatic modulator’• Endogenous purine nucleoside

Page 3: Adenosine and adenosine receptors

Very short halflife (1.5 s) rapid metabolism

Page 4: Adenosine and adenosine receptors

• 4 cell surface receptors namely A1, A2a, A2b and A3

• Until now adenosine was mainly used for terminating paroxysmal supraventricular tachycardia (PSVT) and Wolff Parkinson White (WPW) syndrome.

• Advances in understanding of adenosine receptors development of agonists and antagonists

Page 5: Adenosine and adenosine receptors

Adenosine Receptors

Page 6: Adenosine and adenosine receptors
Page 7: Adenosine and adenosine receptors

A3

A2AA2B

A1(Very high affinity)

(High affinity) (Low affinity)

(Low affinity)

Gi

Gs

ACKATPPLC Ca2+PLA2

Isoforms have distinct, but overlapping, cellular distributionand are widely expressed inmost cells/tissues/organs of the body.

Adenosine Receptors: SignalTransduction Mechanisms

Page 8: Adenosine and adenosine receptors
Page 9: Adenosine and adenosine receptors

Newer potential therapeutic role of adenosine and its receptors

1. Bronchial asthma:

• AMP induces bronchoconstriction in asthmatic pts (only) • Adenosine levels are increased in BAL fluid ,exhaled breath

condensate.• Adenosine induces hyperresponsiveness in the airways of

asthmatics, in vivo following inhalation and in vitro in small airways.• At therapeutic plasma levels, less than those required to inhibit

phosphodiesterase enzyme,Theophylline, a nonselective adenosine receptor antagonist & Bamiphylline, a selective A1 adenosine receptor antagonist improve lung function and symptoms in humans with asthma.

• All the 4 adenosine receptors, are targets for drug development for human asthma.

Page 10: Adenosine and adenosine receptors
Page 11: Adenosine and adenosine receptors

Refractory primary pulmonary hypertension (RPPH)

• PPHN is a serious disease in which the pulmonary vascular resistance remains elevated during the neonatal period.

• Occurs in association with diverse neonatal cardiorespiratory disorders(meconium aspiration, sepsis, pneumonia, acute respiratory distress syndrome, asphyxia, CDH or lung hypoplasia)

• PPHN of the newborn contributes to neonatal hypoxemia, which is often refractory morbidity and mortality in term and preterm neonates.

Page 12: Adenosine and adenosine receptors

• treated by correcting the primary and triggering factors• Ventilation strategies / electrolytic and acid base balance/

nutritional support /nonspecific agents ( alkali infusion, magnesium sulphate, prostacyclin, tolazoline ) & pulmonary vasodilator agents (nitric oxide.)

• Adenosine infusion for PPHN, alone or associated with other strategies (refractory cases)

• The pathophysiologic hypothesis pulmonary vasodilation is achieved by two known pathways.

1. Nitric oxide elevating intracellular cGMP levels Smt muscle relaxation vasodilator effect.

2. Adenosine selective pulmonary vasodilation by acting at A2 receptors on vascular smooth muscle to increase intracellular cyclic AMP smt muscle relaxation & improvement in systemic & myocardial O2 delivery. Adenosine may also stimulate K+ ATP channels, resulting in hyperpolarization of smooth muscle.

Page 13: Adenosine and adenosine receptors

Inflammatory bowel diseases (IBDs)• Traditional treatments nonspecific suppression of

immune reaction and inflammation • Enteric immunopathogenesis targeted therapies• Adenosine system and its involvement in the

pathophysiology of IBDs.• Once released at sites of inflammation, adenosine plays

prominent roles in maintaining tissue integrity - 1. By modulation of immune functions2. Downregulation of phlogistic reactions3. Interference with the biosynthesis of

proinflammatory cytokines and inhibition of neutrophil adhesion, degranulation.

4. Antioxidant activity.

Page 14: Adenosine and adenosine receptors

• Concentrations of adenosine closely reflect the metabolic status of the tissue

• Been proposed that The Purinergic System act as a sensor apparatus, which provides immune system information about tissue health

• GIT tract, adenosine control of ENS & smt muscle contractility

• Under physiological conditions, adenosine is mainly formed at the intracellular level from S-adenosyl homocysteine hydrolase.

• In cases of hypoxia or inflammation, adenosine production occurs both intracellularly and extracellularly by dephosphorylation of ATP via 5'nucleotidase enzymes + by suppression of adenosine kinase activity

Page 15: Adenosine and adenosine receptors
Page 16: Adenosine and adenosine receptors
Page 17: Adenosine and adenosine receptors

• Direct stimulation of adenosine receptor subtypes A2a & A3 treatment of IBDs.

• ATL146e, a selective A2a receptor agonist, acute / chronic model of colitis(formalin immune complex in rabbits) & spontaneous ileitis in SAMP1/YitFc mice anti inflamatory axn

• Stimulation of A2a receptors significant decrease in inflammation in the intestinal mucosa, with a reduction of leucocyte infiltration & inhibition of proinflammatory cytokine levels (TNFα, IFNγ and IL4).

• A3 receptor agonist significant ameliorative effects, both in DSS induced intestinal inflammation and spontaneous colitis in IL10 deficient mice.

Page 18: Adenosine and adenosine receptors

Anaesthesia and intensive care medicine

• Pain reducing effects of intravenous adenosine infusion (50–70 mg/kg/min.)

• Effectiveness of adenosine in reducing ischaemic pain is comparable to morphine or ketamine

• Adenosine given in combination with morphine or ketamine additive effect on pain reduction

• Adenosine infusion during GA for surgery provided good recovery from anaesthesia, associated with pronounced and sustained postoperative pain relief.

• Acts by inhibiting nociceptive transmission.

Page 19: Adenosine and adenosine receptors

Epilepsy

• Adenosine is an inhibitory modulator of brain activity.

• By activation of A1 receptors in hippocampus predominant inhibitory effects can suppress seizures and maintaining postictal depression and restore metabolic equilibrium following seizures

• Pathogenic role of the adenosine system in epileptogenesis remains understudied.

Page 20: Adenosine and adenosine receptors

Ischaemia/reperfusion (I/R) Injury

• Ischaemic preconditioning (IPC) refers to the mechanism whereby brief periods of ischaemia/reperfusion render a tissue relatively resistant to the harmful effects of subsequent prolonged periods of ischaemia/reperfusion.

‘Adenosine Theory’ supported by three facts:1. Interstitial adenosine concentration doubles after 5

min of cardiac ischaemia.2. Adenosine antagonists reduce the effect of cardiac IPC.3. Adenoreceptor stimulation reduces myocardial damage

following ischaemia / reperfusion & during cardiopulmonary bypass

Page 21: Adenosine and adenosine receptors

Reperfusion Injury• Conversion of reversibly injured endothelial and

myocardial cells to irreversibly injured cells

Myocardial Stunning• Prolonged left ventricular dysfunction of reversibly

injured myocytes

Reperfusion Arrhythmias

Potential Sequelae of Reperfusion on Ischemic Myocardium

Page 22: Adenosine and adenosine receptors

• Definition: Conversion of reversibly injured endothelial and myocardial cells to irreversibly injured cells during the peri-reperfusion period.

Not synonymous with entity of acceleration of necrosis of cells that are already irreversibly injured.

Myocardial Reperfusion Injury

Page 23: Adenosine and adenosine receptors

Effects of Adenosine A1

SA NODE AV NODE VENTRICLE MYOCYTE BLOOD VESSELS

Θ Θ Θ Θ

CHRONOTROPIC EFFECT

DROMOTROPIC EFFECT

INOTROPIC EFFECT

PRE- & POST- CONDITIONING

NEURO-TRANSMITTER

RELEASE

A1

Page 24: Adenosine and adenosine receptors

Effects of Adenosine A2A/A2B

VESSELS PLATELETS NEUTROPHILS VSMC’S & CARDIAC

FIBROBLASTS

ENDOTHELIAL CELL

Θ Θ Θ

DILATATION AGGREGATION TxB2 RELEASE

ADHERANCE TO EC’s & FREE

RADICAL RELEASE

PROLIFERATION & MIGRATION

AND ECM PRODUCTION

ANGIO- & VASCULO- GENESIS

A2A/A2B

Page 25: Adenosine and adenosine receptors

Effects of Adenosine A3

MYOCYTE ENDOTHELIALVSM CELLS

PRE-CONDITIONING,↑ANTI-OXIDANT

ENZYMES

↑ANTI-OXIDANTENZYMES

A3

Page 26: Adenosine and adenosine receptors

Reperfusion

Mechanisms of Myocardial Reperfusion Injury and Effects of Adenosine

LeukocytesTxA2, PAF,Ang II, NE, ET-1

Calcium OxygenPlatelets

A2A/2B AngiogenesisVasculogenesis

MPOProteases

Cellular CalciumOverload

PlateletAggregation

VasoconstrictionOxygenFreeRadicals

No Reflow

Vascular Plugging

Cell Death

A2A A2AA2A A1

A3

ADENOSINE

Page 27: Adenosine and adenosine receptors

Transverse Myocardial Slice in Adenosine and Control Animal

Page 28: Adenosine and adenosine receptors

• Adenosine may attenuate ischaemia / reperfusion injury by a number of possible mechanisms-

1. purine salvaging2. Improved Tissue Perfusion At high doses

adenosine + reduces capillary hyperpermeability + leucocyte adherence + leucocyte extravasation

3. antiinflammatory action reduction in granulocyte respiratory burst activity

4. direct intracellular initiator/effector mechanism.

Page 29: Adenosine and adenosine receptors

Sepsis:• Strongly inhibit extracellular superoxide anion

release.• The higher dose acadesine treatment had the

following effects: Reduced the endotoxin induced increase in alveolar protein extravasation, systemic oxygen consumption and cardiac index.

• Reduced the endotoxin induced hypoxia and early transient pulmonary hypertension.

• Reduced the fluid requirement necessary to maintain systemic hemodynamics.

• Reduced mortality and prolonged survival time .

Page 30: Adenosine and adenosine receptors

Parkinson's disease

• Istradefylline (KW6002) is an adenosine A2a receptor antagonist that is now in phase III clinical trials for PD.

• Relatively specific A2a receptor antagonists consistently reverse motor deficits or enhance dopaminergic treatments in animal models.

Page 31: Adenosine and adenosine receptors

Hypolipidaemic agent

• RPR749 is a potent and selective adenosine A1 agonist hypertriglyceridaemia CAD pts.

• RPR749 (0.1–30 mg/kg) has been shown to reduce TG levels from 20 to 70%

Page 32: Adenosine and adenosine receptors

Conclusions• Very useful therapeutic tool• Alternatives to adenosine administration include modulation of its

metabolism and administration of specific agonists/antagonists like

1. Adenosine precursors (e.g. acadesine).2. Adenosine analogues—A1 antagonists and A2 agonists both of

which are anti-inflammatory.3. Adenosine metabolism inhibitors that increase the

concentration of endogenous adenosine. These are:• Adenosine deaminase inhibitors (e.g. pentostatin)• Adenosine kinase inhibitors (e.g. GP515)• Nucleoside transport inhibitors (e.g. R75231). By preventing the

uptake of extracellular adenosine into cells, endogenous adenosine is protected from metabolism by adenosine deaminase.

Page 33: Adenosine and adenosine receptors

Reference • S. Manjunath and Pranavkumar M. Sakhare.Adenosine and

adenosine receptors: Newer therapeutic perspective. Indian J Pharmacol. 2009 Jun; 41(3): 97–105.

• Purinergic Signaling, American Society for Neurochemistry. Published by Elsevier . 2012

• Mervyn B. Forman, Role of Adenosine in Acute Myocardial Infarction.(ppt online)

• Arch JR, Newsholme EA. The control of the metabolism and the hormonal role of adenosine. Essays Biochem. 1978;14:82–123.

• Peralta C, Hotter G, Closa D. Protective effect of preconditioning on the injury associated to hepatic ischaemiareperfusion in the rat: Role of nitric oxide and adenosine. Hepatology. 1997;25:934–37.

Page 34: Adenosine and adenosine receptors

Thank you